Stock Screener
Stock Research
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

Ironwood Pharmaceuticals Long Term Debt 2010-2025 | IRWD

Ironwood Pharmaceuticals long term debt from 2010 to 2025. Long term debt can be defined as the sum of all long term debt fields.
  
Ironwood Pharmaceuticals Annual Long Term Debt
(Millions of US $)
2024 $584
2023 $498
2022 $396
2021 $0
2020 $430
2019 $408
2018 $366
2017 $396
2016 $367
2015 $354
2014 $161
2013 $178
2012 $0
2011 $0
2010 $0
2009 $1
Ironwood Pharmaceuticals Quarterly Long Term Debt
(Millions of US $)
2025-03-31 $584
2024-12-31 $584
2024-09-30 $599
2024-06-30 $624
2024-03-31 $473
2023-12-31 $498
2023-09-30 $523
2023-06-30 $598
2023-03-31
2022-12-31 $396
2022-09-30 $396
2022-06-30 $395
2022-03-31 $395
2021-12-31
2021-09-30 $333
2021-06-30 $329
2021-03-31 $436
2020-12-31 $430
2020-09-30 $425
2020-06-30 $419
2020-03-31 $426
2019-12-31 $408
2019-09-30 $403
2019-06-30 $353
2019-03-31 $360
2018-12-31 $366
2018-09-30 $370
2018-06-30 $380
2018-03-31 $388
2017-12-31 $396
2017-09-30 $392
2017-06-30 $388
2017-03-31 $384
2016-12-31 $367
2016-09-30 $363
2016-06-30 $339
2016-03-31 $349
2015-12-31 $354
2015-09-30 $360
2015-06-30 $364
2015-03-31 $160
2014-12-31 $161
2014-09-30 $168
2014-06-30 $171
2014-03-31 $173
2013-12-31 $178
2013-09-30 $178
2013-06-30 $175
2013-03-31 $175
2012-12-31 $0
2012-09-30 $0
2012-06-30 $0
2012-03-31 $0
2011-12-31 $0
2011-09-30 $0
2011-06-30 $1
2011-03-31 $1
2010-12-31 $0
2010-09-30 $0
2010-06-30 $2
2010-03-31 $2
2009-12-31 $1
2009-09-30 $2
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.129B $0.351B
Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of treatments primarily addressing gastrointestinal diseases. Linzess was launched in collaboration with Allergan for patients suffering from irritable bowel syndrome (IBS-C; 290 mcg) with constipation or chronic idiopathic constipation. Ironwood and AbbVie co-develop & co-commercialize Linzess in all other territories world wide. Linzess is marketed by Allergan for IBS-C in Europe and Canada under the brand name Constella. The company receives royalties on sales of Constella in Europe and Canada from AbbVie. In Japan, it has partnered with Astellas Pharma for the development and commercialization of Linzess and with AstraZeneca in China, Hong Kong & Macau. Linzess received approval for IBS-C indication in Japan for chronic constipation and in China for IBS-C. The company completed the spin-off of its soluble guanylate cyclase segment into a separate, publicly traded company, Cyclerion Therapeutics.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) Japan $81.683B 31.42
Zoetis (ZTS) United States $67.115B 25.04
Daiichi Sankyo, - (DSNKY) Japan $46.355B 23.76
Takeda Pharmaceutical (TAK) Japan $45.533B 9.06
BeOne Medicines - (ONC) Cayman Islands $32.278B 0.00
Sandoz Group AG (SDZNY) Switzerland $26.052B 0.00
Summit Therapeutics (SMMT) United States $20.386B 0.00
Merck (MKKGY) Germany $16.931B 12.40
Shionogi (SGIOY) Japan $15.006B 15.03
United Therapeutics (UTHR) United States $13.448B 11.90
Neurocrine Biosciences (NBIX) United States $13.233B 45.33
Orion OYJ (ORINY) Finland $11.504B 27.72
IPSEN (IPSEY) France $10.846B 0.00
Stevanato Group S.p.A (STVN) Italy $7.865B 48.09
Corcept Therapeutics (CORT) United States $7.333B 59.61
Grifols, S.A (GRFS) Spain $6.937B 0.00
Ionis Pharmaceuticals (IONS) United States $6.553B 0.00
Madrigal Pharmaceuticals (MDGL) United States $6.531B 0.00
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $6.204B 0.00
Ono Pharmaceutical (OPHLF) Japan $5.214B 15.86
Soleno Therapeutics (SLNO) United States $4.296B 0.00
Hypermarcas (HYPMY) Brazil $2.971B 19.54
Crinetics Pharmaceuticals (CRNX) United States $2.837B 0.00
NewAmsterdam Pharma (NAMS) Netherlands $2.629B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.561B 13.85
Catalyst Pharmaceuticals (CPRX) United States $2.537B 8.89
Centessa Pharmaceuticals (CNTA) United Kingdom $2.031B 0.00
Ocular Therapeutix (OCUL) United States $1.924B 0.00
Endo (NDOI) United States $1.813B 0.00
ARS Pharmaceuticals (SPRY) United States $1.802B 0.00
BioCryst Pharmaceuticals (BCRX) United States $1.728B 0.00
Evotec AG (EVO) Germany $1.513B 0.00
Guardian Pharmacy Services (GRDN) United States $1.313B 0.00
Harrow (HROW) United States $1.279B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.201B 24.03
Dyne Therapeutics (DYN) United States $1.058B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $1.048B 0.00
Ardelyx (ARDX) United States $1.024B 0.00
Enliven Therapeutics (ELVN) United States $1.014B 0.00
Collegium Pharmaceutical (COLL) United States $1.008B 5.43
Akebia Therapeutics (AKBA) United States $0.943B 0.00
ProKidney (PROK) United States $0.902B 0.00
Cronos Group (CRON) Canada $0.795B 0.00
Xeris Biopharma Holdings (XERS) United States $0.793B 0.00
Amylyx Pharmaceuticals (AMLX) United States $0.712B 0.00
KalVista Pharmaceuticals (KALV) United States $0.678B 0.00
Xencor (XNCR) United States $0.643B 0.00
Organogenesis (ORGO) United States $0.637B 0.00
Relay Therapeutics (RLAY) United States $0.634B 0.00
Zevra Therapeutics (ZVRA) United States $0.591B 0.00
Elite Pharmaceuticals (ELTP) United States $0.587B 0.00
USANA Health Sciences (USNA) United States $0.586B 11.77
Tourmaline Bio (TRML) United States $0.581B 0.00
Theravance Biopharma (TBPH) United States $0.553B 0.00
Bioventus (BVS) United States $0.536B 13.60
Oruka Therapeutics (ORKA) United States $0.525B 0.00
Siga Technologies (SIGA) United States $0.515B 10.76
Savara (SVRA) United States $0.460B 0.00
Aquestive Therapeutics (AQST) United States $0.397B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.357B 9.66
Tonix Pharmaceuticals Holding (TNXP) United States $0.348B 0.00
Altimmune (ALT) United States $0.327B 0.00
AleAnna (ANNA) United States $0.321B 0.00
Aldeyra Therapeutics (ALDX) United States $0.319B 0.00
Esperion Therapeutics (ESPR) United States $0.315B 0.00
Nanobiotix S.A (NBTX) France $0.313B 0.00
Nektar Therapeutics (NKTR) United States $0.293B 0.00
Heron Therapeutics (HRTX) United States $0.284B 0.00
Nature's Sunshine Products (NATR) United States $0.272B 24.97
OmniAb (OABI) United States $0.252B 0.00
Larimar Therapeutics (LRMR) United States $0.233B 0.00
MediWound (MDWD) Israel $0.215B 0.00
4D Molecular Therapeutics (FDMT) United States $0.215B 0.00
Liminatus Pharma (LIMN) United States $0.210B 0.00
Lyell Immunopharma (LYEL) United States $0.203B 0.00
Galectin Therapeutics (GALT) United States $0.194B 0.00
Aclaris Therapeutics (ACRS) United States $0.182B 0.00
China SXT Pharmaceuticals (SXTC) China $0.181B 0.00
Journey Medical (DERM) United States $0.179B 0.00
Profound Medical (PROF) Canada $0.171B 0.00
Avita Medical (RCEL) United States $0.153B 0.00
Korro Bio (KRRO) United States $0.147B 0.00
Lexeo Therapeutics (LXEO) United States $0.141B 0.00
Inhibikase Therapeutics (IKT) United States $0.132B 0.00
Protara Therapeutics (TARA) United States $0.129B 0.00
Cardiol Therapeutics (CRDL) Canada $0.126B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.117B 0.00
Cassava Sciences (SAVA) United States $0.115B 0.00
Innate Pharma SA (IPHYF) France $0.110B 0.00
Fractyl Health (GUTS) United States $0.096B 0.00
Vivani Medical (VANI) United States $0.095B 0.00
Metagenomi (MGX) United States $0.094B 0.00
Achieve Life Sciences (ACHV) Canada $0.093B 0.00
VAXART, INC (VXRT) United States $0.093B 0.00
Nutriband (NTRB) United States $0.090B 0.00
Champions Oncology (CSBR) United States $0.087B 19.69
ESSA Pharma (EPIX) Canada $0.083B 0.00
Arch Biopartners (ACHFF) Canada $0.080B 0.00
Surrozen (SRZN) United States $0.080B 0.00
PMV Pharmaceuticals (PMVP) United States $0.078B 0.00
Dominari Holdings (DOMH) United States $0.077B 0.00
Context Therapeutics (CNTX) United States $0.076B 0.00
Pyxis Oncology (PYXS) United States $0.076B 0.00
Wellgistics Health (WGRX) United States $0.075B 0.00
Inotiv (NOTV) United States $0.074B 0.00
Avalo Therapeutics (AVTX) United States $0.071B 0.00
Rafael Holdings (RFL) United States $0.071B 0.00
Assertio Holdings (ASRT) United States $0.069B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.063B 0.00
Telomir Pharmaceuticals (TELO) United States $0.063B 0.00
Unicycive Therapeutics (UNCY) United States $0.060B 0.00
Allergy Therapeutics (AGYTF) United Kingdom $0.059B 0.00
Century Therapeutics (IPSC) United States $0.055B 0.00
ElectroCore (ECOR) United States $0.054B 0.00
Jupiter Neurosciences (JUNS) United States $0.052B 0.00
BioNxt Solutions (BNXTF) Canada $0.052B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.052B 38.67
Klotho Neurosciences (KLTO) United States $0.052B 0.00
NRx Pharmaceuticals (NRXP) United States $0.051B 0.00
Gain Therapeutics (GANX) United States $0.049B 0.00
Prelude Therapeutics (PRLD) United States $0.048B 0.00
Acrivon Therapeutics (ACRV) United States $0.045B 0.00
Mural Oncology (MURA) Ireland $0.042B 0.00
Karyopharm Therapeutics (KPTI) United States $0.038B 0.00
PolyPid (PYPD) Israel $0.037B 0.00
Plus Therapeutics (PSTV) United States $0.035B 0.00
Incannex Healthcare (IXHL) Australia $0.035B 0.00
Iterum Therapeutics (ITRM) Ireland $0.031B 0.00
Enlivex Therapeutics (ENLV) Israel $0.030B 0.00
Tempest Therapeutics (TPST) United States $0.030B 0.00
FibroGen (FGEN) United States $0.029B 0.00
SCYNEXIS (SCYX) United States $0.029B 0.00
Vivos Therapeutics (VVOS) United States $0.028B 0.00
Scienture Holdings (SCNX) United States $0.026B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.024B 0.00
Natural Alternatives (NAII) United States $0.022B 0.00
VYNE Therapeutics (VYNE) United States $0.022B 0.00
Relmada Therapeutics (RLMD) United States $0.021B 0.00
Cosmos Health (COSM) United States $0.020B 0.00
CASI Pharmaceuticals (CASI) China $0.020B 0.00
ProPhase Labs (PRPH) United States $0.018B 0.00
Lipocine (LPCN) United States $0.018B 0.00
BioLineRx (BLRX) Israel $0.018B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.018B 0.00
DURECT (DRRX) United States $0.017B 0.00
Citius Pharmaceuticals (CTXR) United States $0.016B 0.00
Mannatech (MTEX) United States $0.016B 0.00
Carisma Therapeutics (CARM) United States $0.015B 0.00
Minerva Neurosciences (NERV) United States $0.015B 2.56
Ernexa Therapeutics (ERNA) United States $0.014B 0.00
TherapeuticsMD (TXMD) United States $0.014B 0.00
BioVie (BIVI) United States $0.013B 0.00
Phio Pharmaceuticals (PHIO) United States $0.012B 0.00
TransCode Therapeutics (RNAZ) United States $0.012B 0.00
Ainos (AIMD) United States $0.011B 0.00
Lyra Therapeutics (LYRA) United States $0.010B 0.00
Biomerica (BMRA) United States $0.010B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.009B 0.00
Addex Therapeutics (ADXN) Switzerland $0.009B 0.00
Traws Pharma (TRAW) United States $0.009B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.009B 0.00
Talphera (TLPH) United States $0.009B 0.00
Mangoceuticals (MGRX) United States $0.009B 0.00
Aptorum Group (APM) United Kingdom $0.009B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.007B 0.00
Nuvilex (PMCB) United States $0.007B 0.00
Indaptus Therapeutics (INDP) United States $0.006B 0.00
Xenetic Biosciences (XBIO) United States $0.006B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.005B 0.00
InMed Pharmaceuticals (INM) Canada $0.005B 0.00
Alaunos Therapeutics (TCRT) United States $0.005B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.005B 0.00
Qualigen Therapeutics (QLGN) United States $0.005B 0.00
Clearmind Medicine (CMND) Canada $0.004B 0.00
SciSparc (SPRC) Israel $0.004B 0.00
Redhill Biopharma (RDHL) Israel $0.004B 0.00
SHINECO (SISI) China $0.003B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.003B 0.00
XORTX Therapeutics (XRTX) Canada $0.003B 0.00
PainReform (PRFX) Israel $0.003B 0.00
CERo Therapeutics Holdings (CERO) United States $0.003B 0.00
Heatwurx (PCSA) United States $0.003B 0.00
Aditxt (ADTX) United States $0.003B 0.00
Jaguar Animal Health (JAGX) United States $0.002B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.002B 0.00
TNF Pharmaceuticals (TNFA) United States $0.002B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.002B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.002B 0.00
Conduit Pharmaceuticals (CDT) United States $0.002B 0.00
Universe Pharmaceuticals INC (UPC) China $0.000B 0.00
Indivior (INDV) United States $0.000B 9.99
4D Pharma (LBPS) United Kingdom $0.000B 0.00
MEI Pharma (MEIP) United States $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Silence Therapeutics (SLN) United Kingdom $0.000B 0.00